Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer
Mr. From brings over 20 years of leadership in the healthcare and financial industry. He most recently served as CEO of Aruna Bio, guiding the company's strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and CEO, and from February 2021 through January 2022 served as Executive Chairman of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), formerly known as EyeGate Pharmaceuticals, Inc., leading the company through its initial public offering and multiple acquisitions and licensing transactions in the ophthalmic therapeutics space.
Before EyeGate, Mr. From was CFO of Centelion SAS, then a biotech subsidiary of Sanofi‑Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University
'I am honored to join the Vicarious Surgical team at this pivotal time in its evolution. The Company's technology offers a significant advancement from today's surgical approaches with the potential to transform modern surgery and improve outcomes for patients worldwide,' said Mr. From. 'I look forward to working alongside this talented team and Board to advance our strategic priorities and deliver on the promise of this innovative platform.'
'It has been an incredible journey to lead Vicarious Surgical from its inception through pre-clinical testing, and I'm proud of all we've accomplished to date. As I transition into the role of President, I'm excited to welcome Stephen as our new CEO,' said Adam Sachs, current Chief Executive Officer, Co-Founder, and Board member. 'I believe his leadership and experience are exactly what we need at this pivotal stage, and I look forward to working closely with him to advance our mission of transforming surgical care through innovative robotics.'
In connection with the appointment of Mr. From, the Company is also announcing, as required by New York Stock Exchange Listed Company Manual Rule 303A.08 (the 'Inducement Rule'), a stock option award to be made to Mr. From as a material inducement to his entering into employment with the Company. The stock option award was approved by the Company's Board and by its Compensation Committee with a grant date of August 7, 2025.
The stock option to be granted to Mr. From will be exercisable for up to 297,600 shares of the Company's Class A common stock, will have an exercise price equal to the closing price of the Class A common stock on the date of grant, and will expire on the ten-year anniversary of the grant date. One-quarter of the stock options will vest and become exercisable on the one-year anniversary of the grant date, and the remainder of the stock options will vest in thirty-six equal consecutive, equal monthly installments thereafter, subject to Mr. From's continued service to the Company through each vesting date and subject to accelerated vesting in certain circumstances. The stock option award will be made outside of the Company's existing 2021 Equity Incentive Plan, as amended (the 'Plan'), but will be subject to terms and conditions generally consistent with those in the Plan, other than with respect to such terms and conditions intended to comply with the Inducement Rule.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
Forward-Looking Statements
This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the potential for the Company's technology to improve patient outcomes, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of the Company's Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of the Company's initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product and service development activities; the potential attributes and benefits of the Company's product candidates and services; the Company's ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing license, manufacture, supply and distribution agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company's business, financial condition and results of operations; the Company's intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company's filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
McKesson's (NYSE:MCK) Q2 Sales Top Estimates
Healthcare distributor and services company McKesson (NYSE:MCK) announced better-than-expected revenue in Q2 CY2025, with sales up 23.4% year on year to $97.83 billion. Its non-GAAP profit of $8.26 per share was 1.4% above analysts' consensus estimates. Is now the time to buy McKesson? Find out in our full research report. McKesson (MCK) Q2 CY2025 Highlights: Revenue: $97.83 billion vs analyst estimates of $96.48 billion (23.4% year-on-year growth, 1.4% beat) Adjusted EPS: $8.26 vs analyst estimates of $8.15 (1.4% beat) Management slightly raised its full-year Adjusted EPS guidance to $37.50 at the midpoint Operating Margin: 1.1%, in line with the same quarter last year Free Cash Flow was -$1.11 billion compared to -$1.55 billion in the same quarter last year Market Capitalization: $88.76 billion Company Overview With roots dating back to 1833, making it one of America's oldest continuously operating businesses, McKesson (NYSE:MCK) is a healthcare services company that distributes pharmaceuticals, medical supplies, and provides technology solutions to pharmacies, hospitals, and healthcare providers. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, McKesson grew its sales at a decent 10.3% compounded annual growth rate. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. McKesson's annualized revenue growth of 15.3% over the last two years is above its five-year trend, suggesting its demand recently accelerated. We can better understand the company's revenue dynamics by analyzing its most important segment, U.S. Pharmaceutical . Over the last two years, McKesson's U.S. Pharmaceutical revenue averaged 17.6% year-on-year growth. This quarter, McKesson reported robust year-on-year revenue growth of 23.4%, and its $97.83 billion of revenue topped Wall Street estimates by 1.4%. Looking ahead, sell-side analysts expect revenue to grow 10% over the next 12 months, a deceleration versus the last two years. We still think its growth trajectory is attractive given its scale and implies the market is forecasting success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin McKesson was roughly breakeven when averaging the last five years of quarterly operating profits, lousy for a healthcare business. On the plus side, McKesson's operating margin rose by 3.3 percentage points over the last five years, as its sales growth gave it operating leverage. In Q2, McKesson generated an operating margin profit margin of 1.1%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. McKesson's EPS grew at an astounding 18.3% compounded annual growth rate over the last five years, higher than its 10.3% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Diving into the nuances of McKesson's earnings can give us a better understanding of its performance. As we mentioned earlier, McKesson's operating margin was flat this quarter but expanded by 3.3 percentage points over the last five years. On top of that, its share count shrank by 23.1%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth. In Q2, McKesson reported adjusted EPS at $8.26, up from $7.88 in the same quarter last year. This print beat analysts' estimates by 1.4%. Over the next 12 months, Wall Street expects McKesson's full-year EPS of $33.48 to grow 15.5%. Key Takeaways from McKesson's Q2 Results It was good to see McKesson narrowly top analysts' revenue and EPS expectations this quarter. The market seemed to be hoping for more, and the stock traded down 1.8% to $692 immediately following the results. So do we think McKesson is an attractive buy at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
26 minutes ago
- Yahoo
Arista May Outpace Peers With 25% Growth
Arista Networks (NYSE:ANET) opened up 14% Wednesday after smashing Q2 expectations on booming cloud and data center spending. They delivered a 65.6% gross margin, beating guidance of 63% and the Street's 62.9%, while operating margin hit 48.8% versus a 46% forecast. Free cash flow came in at $1.18 billion, well above the $852 million consensus and even BofA's $1.02 billion model. Management now sees 25% revenue growth in 2025, up from 17%, as hyperscalers pour capex into both back-end and front-end cloud networks. Warning! GuruFocus has detected 6 Warning Sign with ANET. Analysts couldn't wait to react: BofA bumped its price target to $155, KeyBanc raised theirs to $145, and J.P. Morgan lifted theirs to $150, all keeping bullish calls. J.P. Morgan's team says Arista could hit $10 billion in revenue by 2026two years ahead of planand that AI network rollouts will keep momentum going into 2027. If Arista can sustain these margins and ride the cloud capex wave, it may leave legacy peers in the will be tuning in to the next earnings report for proof that the cloud boom isn't over. This article first appeared on GuruFocus.
Business Wire
27 minutes ago
- Business Wire
Ralliant Announces Quarterly Dividend
RALEIGH, N.C.--(BUSINESS WIRE)--Ralliant Corporation ('Ralliant' or the 'Company') (NYSE: RAL) announced today that its Board of Directors ('the Board') has approved a quarterly cash dividend of $0.05 per share of its common stock, payable on September 23, 2025 to stockholders of record as of the close of business on September 8, 2025. Tami Newcombe, President and Chief Executive Officer, stated, 'We are making progress against our capital allocation priorities to focus on organic reinvestment, capital return to shareholders, and selective execution of tuck-in acquisitions aligned with our growth vectors. This announcement of our inaugural quarterly dividend, along with our prior announcement of the Board's authorization of up to $200 million of share repurchases demonstrate our commitment to return capital to shareholders.' About Ralliant Ralliant is a global provider of precision technologies that specializes in designing, developing, manufacturing and servicing precision instruments and highly engineered products. Ralliant's two strategic reporting segments — Test & Measurement and Sensors & Safety Systems — include well-known brands with leading positions in their markets. The Company's businesses empower engineers with precision technologies essential for breakthrough innovation that brings advanced technologies to the market faster and more efficiently. With over 150 years of operating experience and enduring customer trust, we are known for delivering innovative, high-quality products with the precision that mission-critical systems demand. Ralliant is headquartered in Raleigh, North Carolina and employs a team of approximately 7,000 research and development, manufacturing, sales, distribution, service and administrative employees. The Company's global footprint enables a unique 'engineer to engineer' approach, which allows it to build enduring trust, credibility, and partnerships with customers across both Fortune 1000 companies and next generation start-up enterprises. With a culture rooted in continuous improvement, the core of our company's operating model is the Ralliant Business System. For more information please visit: Forward-Looking Statements Certain statements included in this press release are 'forward-looking statements' within the meaning of the U.S. federal securities laws. All statements other than historical factual information are forward-looking statements, including, without limitation, statements regarding: business outlook and priorities; future financial performance and results, including outlook and guidance; revenue growth; cash flows, our liquidity position or other financial measures; management's plans and strategies for future operations and growth, including statements relating to anticipated operating performance, cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions, divestitures, strategic opportunities, shareholder value creation, capital allocation priorities, stock repurchases and dividends; the effects of the separation from Fortive on our business; growth, declines and other trends in markets we sell into, including the expected impact of trade and tariff policies; changes in government contracting requirements and reductions in federal spending; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; tax rates, tax provisions, and the impact of changes to tax laws; general economic and capital markets conditions, including expected impact of inflation or interest rate changes; impact of geopolitical events and other hostilities; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that we intend or believe will or may occur in the future. Terminology such as 'believe', 'expect', 'anticipate', 'forecast', 'positioned', 'intend', 'plan', 'project', 'estimate', 'grow', 'will', 'should', 'could', 'would', 'may', 'strategy', 'opportunity', 'possible', 'potential', 'outlook', 'target', and 'guidance' and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to the risks and uncertainties set forth under 'Cautionary Statement Concerning Forward-Looking Statements', 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's Information Statement filed as an exhibit to the Company's Form 10-12B/A with the U.S. Securities and Exchange Commission (the 'SEC') on May 28, 2025, and in other documents that we have filed with, or furnished to, the SEC. Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Forward-looking statements speak only as of the date they are made (or such earlier date as may be specified in such statement). Except to the extent required by applicable law, Ralliant assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, and developments or otherwise.
